NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank recognized for providing financing and advisory services to emerging growth companies worldwide, today announced that it will be a sponsor of the Stem Cell Meeting on the Mesa Investor and Partnering Forum to be held at the Sanford Consortium for Regenerative Medicine in La Jolla, California from November 29 to December 1, 2011.
The Stem Cell Meeting on the Mesa is a two-day conference that brings together the scientific research and business development communities in regenerative medicine with the goal of advancing the latest in stem cell science and research into tangible cures for debilitating diseases and injuries.
ROTH Capital Partners is proud to participate in the event as a panel sponsor. Lisa Walters-Hoffert, Managing Director of Healthcare Investment Banking, will moderate a panel discussion on December 1 from 1:45 p.m. to 3:00 p.m. Pacific Time on “ACCESS TO FINANCE: INDUSTRY WIDE ISSUES”. The panel will include industry experts from the pharmaceutical industry as well as the venture capital community. Specifically, the panel will review recent financing transactions in the private and public markets, notable acquisitions, non-traditional financing strategies, current areas of interest of both financial and strategic investors and the challenges going forward in the funding of innovative regenerative medicine programs.
The conference will host more than 35 corporate presentations and six panels focused on the business of regenerative medicine. It will also feature a nationally recognized Scientific Symposium attended by leading scientists and researchers as well as the first-ever Investor and Partnering Forum designed to facilitate a bridge between academia and industry and further the translation of clinical research through one-on-one meetings. Among the featured speakers for the Scientific Symposium and Partnering Forum are Greg Lucier, Chairman & Chief Executive Officer, Life Technologies Corporation, Matthias Steger, PhD, MBA, Global Head Research & Technology Partnering, Roche Ltd, Sir Ian Wilmut, FRS, FRSE, Director, MRC Centre for Regenerative Medicine, University of Edinburgh and Rudolf Jaenisch, Ph.D., Founding Member, Whitehead Institute; Professor, Biology, Massachusetts Institute of Technology.
The Forum expects to attract approximately 250 participants from international and domestic regenerative medicine companies, large pharmaceutical companies, institutional investors, suppliers and service providers, as well as academic and research institutions. An additional highlight will be the presentation of research findings from six “Disease Teams” of The California Institute for Regenerative Medicine (CIRM). These Teams are focused on developing stem cell-based therapies for brain tumors, type 1 diabetes, sickle cell disease, amyotrophic lateral sclerosis and HIV/AIDS.
To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor and Partnering Forum, please visit www.stemcellmeetingonthemesa.com. Registration is complimentary for credentialed members of the media.
About ROTH Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on identifying opportunities for institutional investors in U.S.-listed equity securities of companies based in the U.S. and China. Headquartered in Newport Beach, CA, with offices throughout the U.S., Hong Kong and a Shanghai Representative Office, the employee-owned firm provides analytical research, trading, capital raising, and business combination advisory services. ROTH seeks to implement innovative financing strategies to efficiently meet the liquidity and valuation requirements of both its corporate and institutional investor clients. www.roth.com
About The Alliance for Regenerative Medicine (ARM):
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.